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R
egulated transcription of specific genes is one of the
fundamental processes that underlie all of human
physiology. As a result, the mis-regulation of tran-
scription is related to almost all of human pathophys-
iology as either a cause or a consequence.1–4 This real-
ization has spurred intense interest in uncovering the funda-
mental characteristics of transcriptional regulation and,
further, in the eventual development of molecules capable of
regulating transcription in living systems and acting as tran-
scription-based therapeutics.1,5 One of the greatest challenges
has been the identification of molecules that can either inhibit
or mimic the function of transcriptional activators and by
doing so precisely regulate the expression of preselected
genes.6,7
Transcriptional activators initiate transcription by binding
to DNA and facilitating the assembly of the transcriptional
machinery through one or more direct binding interactions
with coactivator proteins within the RNA polymerase II
holoenzyme.8 Activator-coactivator interactions thus play an
essential role in the gene activation process, yet there are
many unanswered questions surrounding these binding
events.5 Activators utilize a transcriptional activation domain
(TAD) to bind to the transcriptional machinery and the larg-
est and most well-studied class is the amphipathic class,
named for the interspersed polar and hydrophobic amino
acids present in the TAD sequences. Several lines of evidence
suggest that amphipathic transcriptional activators interact
with a shared group of coactivators within the transcriptional
machinery; in vitro crosslinking experiments, for example,
have shown that the coactivators Med15, Tra1, and Taf12 are
targeted by the activators Gcn4 and Gal4.9,10 There is also
emerging evidence that coactivators may use a single binding
site to interact with a diverse group of activators.11–17 This is
surprising because the TADs of amphipathic activators have
little or no sequence homology, suggesting that either these
diverse sequences must be able to fold into similar structures
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ABSTRACT:
Both genetic and biochemical data suggest that
transcriptional activators with little sequence homology
nevertheless function through interaction with a shared
group of coactivators. Here we show that a series of
peptidomimetic transcriptional activation domains
interact under cell-fiee and cellular conditions with the
metazoan coactivator CBP despite differences in the
positioning and identity of the constituent functional
groups. Taken together, these results suggest that a key
activator binding site within CBP is permissive, accepting
multiple arrangements of hydrophobic functional groups.
Further, this permissiveness is also observed with a
coactivator from S. cerevisiae. Thus, the design of small
molecule mimics of transcriptional activation domains
with broad function may be more straightforward than
previously envisioned. # 2008 Wiley Periodicals, Inc.
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or that the binding sites within the coactivators are permis-
sive, accepting more than one arrangement of hydrophobic
and polar functional groups. Here we use peptidomimetics to
show that one of the primary activator binding sites within
the coactivator CBP (CREB binding protein) can interact in
cell-free and cellular systems with several amphipathic scaf-
folds and is thus quite permissive. Further, we demonstrate
that this permissiveness is conserved from yeast through met-
azoans in the case of a common activator-binding motif.
The coactivator and histone acetyl transferase CBP assimi-
lates signals from a variety of transcriptional activators,
including p53,18–20 Hif1a,21 Tax,22 MLL17 and CREB11 and
thereby plays an integral role in cellular processes as diverse
as hypoxic response and memory formation. CBP is the
founding member of the small but growing class of GACKIX
coactivators that use a 3-helix KIX domain to interact with
the TADs of activators and is one of the most structurally
well-characterized eukaryotic coactivators (Figure 1a).23 The
KIX domain of CBP interacts with the TADs of CREB,11 c-
Myb,12 and others in addition to the artificial TADs KBP 1.66
and KBP 2.20 (Figure 1b).24 Despite significant differences in
sequence, these TADs are proposed to interact with a single
binding site within the KIX domain through the formation
of an amphipathic helix with the hydrophobic residues indi-
cated mediating the important contacts. The CBP KIX
domain is thus an excellent coactivator in which to investi-
gate the permissiveness of activator binding sites. To this
FIGURE 1 The GACKIX domain of CBP is targeted by many eukaryotic activators. (a) Solution
structure of CBP(586-666) in complex with the activation domain of CREB (PDB accession num-
ber 1KDX).11 (b) Sequences of four transcriptional activation domains that interact with the CBP
GACKIX domain. CREB and c-Myb are natural activators whereas KBP 1.66 and 2.20 were isolated
via phage display screen against KIX.24 (c) Helical representations of the natural, enantiomeric and
b-peptide versions of the KBP 2.20 TAD; no structure of the peptoid version is provided as it is dif-
ficult to predict peptoid conformation. (d) Helical representations of the natural, enantiomeric,
and b-peptide versions of the KBP 1.66 TAD.
Table I Dissociation Constants for the Interaction of KBP 2.20
and 1.66 Derivatives with the GACKIX Domains of CBP and
Med 15
CBP(586-672) Med15(1-345)
KBP 2.20 346 2 lM 76 1 lM
d-KBP 2.20 286 3 lM 4.5 6 .3 lM
b-KBP 2.20 206 2 lM 4.7 6 .5 lM
peptoid 2.20 5.5 6 .2 lM [30 lM
KBP 1.66 766 10 lM 10.8 6 .6 lM
d-KBP 1.66 846 11 lM 12.4 6 .7 lM
b-KBP 1.66 206 1 lM 126 1 lM
Peptoid 1.66 N.B. N.B.
Fluorescein-labeled peptides or peptidomimetics at a constant concentra-
tion were individually incubated at 258C with increasing concentrations of
either CBP or Med15. The fluorescence polarization at each concentration
was measured and the resulting data fit using the Levenberg-Marquardt least
squares method to obtain the dissociation constants. Each experiment was
performed in triplicate (R2[ 0.98) with the error indicated. See Supporting
Information for details and binding curves.
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end, peptidomimetic variants of KBP 1.66 and 2.20 were
designed that would alter the presentation and spacing of the
functional groups within the sequence; the d-peptide version
would produce the enantiomeric arrangement of functional
groups for interaction, the b-peptide would be predicted to
form a 14-helix upon binding and thus change the spacing
and the hydrophobic interface, and the peptoid analog would
have the N-H hydrogen bonds removed (Figures 1c and 1d).
The synthesis of each of the peptides and peptidomimetics
was carried out on solid support using established proto-
cols.25–27 Each of the ligands was fluorescently labeled at their
amino termini and fluorescence polarization was used to
determine their respective binding affinities (Table I) for an
exogenously expressed murine CBP KIX domain (CBP(586-
672)). Consistent with earlier observations, KBP 2.20 exhibits
an 3-fold lower dissociation constant for the KIX domain
relative to KBP 1.66; this is likely due to the smaller hydro-
phobic interface of KBP 1.66, predicted to consist of only two
residues rather than the three residues of KBP 2.20.24 Of the
peptidomimetics examined, only the KBP 1.66-derived pep-
toid failed to interact with the target protein to a detectable
extent. This may reflect the loss of one or more key hydrogen
bonds relative to the parent peptide. Remarkably, the b-pep-
tide KBP 1.66 exhibited a 3-fold enhancement in affinity rela-
tive to the parent peptide. Again assuming that the ligands
interact with the KIX domain as amphipathic helices, the 14-
helix of b-KBP 1.66 would have a hydrophobic surface of
three residues (L-L-F) rather than two (Figure 1d).28
Coactivators often have two or more binding sites for tran-
scriptional activation domains and the KIX domain is no
exception, containing two distinct binding surfaces for activa-
tors; these sites can be simultaneously occupied.29 To test if
the peptidomimetic versions of KBP 1.66 and 2.20 bound to
the same site as the peptide versions, we carried out competi-
tive inhibition experiments in HeLa cells (see Figure 2). In
these experiments, a firefly luciferase reporter gene was placed
under the control of Gal4(1-148)1KBP 2.20 that was consti-
tutively expressed. Increasing concentrations of KBP 2.20,
FIGURE 2 Results from luciferase assays in HeLa cell culture. (a) Activity of Gal4(1-148)1KBP
2.20 in the presence of increasing concentrations (0 ? 20 lM) of KBP 2.20 (black line), d-KBP 2.20
(orange line), b-KBP 2.20 (green line), or peptoid KBP 2.20 (blue line) expressed as percent activa-
tion (activity of Gal4(1-148)1KBP 2.20 at each concentration of KBP 2.20 derivative relative to ac-
tivity of Gal4(1-148)1KBP 2.20 alone). Compounds were added to cells as a solution in dimethyl-
sulfoxide (DMSO)/EtOH (70:30 mixture) 3 h after transfection such that the final concentration of
DMSO was \1% (vol/vol). Activity was measured 40 h after compound addition. (b) Activity of
Gal4(1-148)1KBP 2.20 in the presence of increasing concentrations (0 ? 20 lM) of KBP 1.66
(black line), d-KBP 1.66 (orange line), b-KBP 1.66 (green line), or peptoid KBP 1.66 (blue line)
expressed as percent activation as described for a). In all of these experiments cell viability was unaf-
fected by the addition of the peptides or the peptidomimetics as assessed by growth rate, cell num-
ber, and visual inspection. In addition, no impact on the expression of Renilla luciferase (included in
each experiment as a control) was observed, an indication that the molecules are not general inhibi-
tors of transcription in this concentration range. See Supporting Information for details.
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KBP 1.66, or the peptidomimetic analogs were added to the
cells and the change in KBP 2.20-mediated transcription
assessed through alterations in firefly luciferase activity. As
illustrated in Figure 2, peptides KBP 2.20 and 1.66 showed lit-
tle or no inhibitory activity. This was not unexpected since
these short peptides should be rapidly degraded by proteolysis.
However, the peptidomimetic TADs that bound to the KIX
domain inhibited KBP 2.20-mediated transcription up to 75%
at 20 lM concentrations; similar results were obtained with
Gal4(1-148)1KBP 1.66 as the activator (data not shown). In
contrast, a d-peptide in which two of the key hydrophobic res-
idues of KBP 2.20 were replaced with Arg (SRAVRELLFGS)
had no impact on KBP 2.20-mediated transcription despite
exhibiting similar cellular uptake and nuclear localization as
the most effective of the inhibitors, peptoid KBP 2.20 (see
Supporting Information for details). Taken together, these
results are consistent with the peptidomimetic versions of the
KBP TADs interacting with the same binding site, the binding
site that the KBP 2.20 and 1.66 TADs employ for transcrip-
tional activation. Importantly, these data also suggest that the
TAD binding site is permissive, interacting with several differ-
ent presentations of hydrophobic functional groups.
As described earlier, the KIX domain has been identified in
a growing number of coactivators including Med15, a coactiva-
tor that has no direct metazoan homolog.23 Since it has been
proposed that this domain is a transcriptional activator-bind-
ing interface conserved throughout eukaryotes, we were inter-
ested to see if the permissive character of the putative activator
binding sites was also conserved. To test this, we assessed the
ability of each of the KBP 2.20 and KBP 1.66 variants to inter-
act with Med15(1-345). As shown in Table I, all bound well to
the protein with the exception of the peptoids. Importantly,
this is a direct demonstration of a significantly conserved acti-
vator binding surface from yeast to metazoans. It is thus not
surprising that amphipathic activators tend to function in all
eukaryotes regardless of their species of origin.30–32
The observation that at least one key activator binding
site is permissive has significant implications for the discov-
ery of artificial transcriptional activators and of molecules
designed to inhibit activator-coactivator interactions. Per-
haps most important is that it suggests that it is not necessary
to precisely reconstitute a three-dimensional array of amphi-
pathic functional groups within a small molecule in order to
target activator binding sites within coactivators. Thus the
identification of new classes of small molecule activators may
be more straightforward than previously envisioned.
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